Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash	$ 1,310	$ 3,845
Prepaid expenses	1,230	299
Other current assets	232	197
Total current assets	2,772	4,341
Patent acquisition costs, net		14
Total assets	2,772	4,355
Current liabilities:
Accounts payable	3,208	1,671
Accrued expenses	1,530	1,566
Warrant liability	604	1,253
Other current liabilities	983	94
Total current liabilities	6,325	4,584
Commitments and contingencies (Note 9)
Shareholders' deficit:
Share capital of $0.0001 par value Authorized: 45,122,321,523 ordinary shares at March 31, 2024 and December 31, 2023, respectively; issued and outstanding: 15,973,121,298 and 13,234,315,298 at March 31, 2024 and December 31, 2023, respectively	1,598	1,324
Additional paid-in capital	176,443	174,754
Capital redemption reserve	52,194	52,194
Accumulated other comprehensive loss	(761)	(1,040)
Accumulated deficit	(233,027)	(227,461)
Total shareholders' deficit	(3,553)	(229)
Total liabilities and shareholders' deficit	$ 2,772	$ 4,355